Pharmacy Innovations

Has Pharmacy Innovations received an FDA warning letter about GLP-1 drugs?

No FDA warning letter to Pharmacy Innovations naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 1 drug recall report for it naming semaglutide, the latest initiated Dec 22, 2022.

FDA records in this index name Pharmacy Innovations on Dec 22, 2022.

Type named in FDA records
Not stated
FDA warning letters
0
Drug recall reports
1
Drugs named
Semaglutide
Latest record
Dec 22, 2022

FDA warning letters

No FDA warning letters in this index.

Drug recalls

Record
Dec 22, 2022SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 2MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 4MG/ML (0.5ML ...Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.Class IITerminatedD-0236-2023

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.